Guidelines on the diagnosis of primary immune thrombocytopenia in children and adolescents: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2012

Braga, Josefina Aparecida Pellegrini; Loggetto, Sandra Regina; Hoepers, Andréa Thives de Carvalho; Bernardo, Wanderley Marques; Medeiros, Letícia Ferreira; Veríssimo, Mônica Pinheiro de Almeida

doi:10.5581/1516-8484.20130105

Cited by 7 publications

(4 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A platelet count >100 x 10-9 may also indicate a positive response to thrombolytic treatment. (13) Alteplase is a thrombolytic agent often used in cases of central venous catheter thrombosis to achieve local clot lysis with intracatheter administration. However, careful monitoring is required as systemic administration increases the possibility of local blood vessel damage and the formation of new thrombi.…”

Section: Discussionmentioning

confidence: 99%

Fibrinolytic therapy in newborns with superior vena cava syndrome. Case report

et al. 2020

View full text Add to dashboard Cite

Introduction: Superior vena cava syndrome is described as the obstruction of blood flow through the superior vena cava. The literature reports that the incidence of this pathology varies from 1 case in every 650 inhabitants and 1 case in every 3 100 inhabitants. Since this condition is very rare in the pediatric population, no clear figure has been reported regarding its incidence in children. The use of a central venous catheter in newborns is a risk factor for this condition, as it may cause a thrombus due to the inflammatory reaction against the device. Therefore, it is necessary to initiate anticoagulation management and remove the catheter.Case presentation: Premature male newborn, (31.4 weeks gestation), with acute respiratory distress syndrome, early neonatal sepsis, pneumonia, necrotizing enterocolitis on 2 occasions, intestinal obstruction due to adhesions and intestinal volvulus. At 90 days of age, he presented thrombosis of the superior vena cava without involvement of the jugular and subclavian vein junction in the right atrium. Anticoagulant management was started, but given his unfavorable evolution, a multidisciplinary medical board was held to assess the risks, benefits, and treatment options in this age group. It was decided to start intracavitary tissue plasminogen activator treatment associated with mechanical thrombectomy and angioplasty of the superior vena cava. Due to the difficulty of conducting clinical trials in this population and the rates of major bleeding complications obtained with thrombolytic therapies, there is very little information available on the use of tissue plasminogen activator in newborns. For this reason, alteplase is seldom considered as the therapy of choice. However, in patients with life-threatening thrombosis, such as the present case, the results obtained in adults could be extrapolated in search of a favorable outcome.Conclusions: Fibrinolytic therapy is a way to reduce the size of the thrombus, but it dramatically increases the risk of bleeding; consequently, these patients must be strictly monitored. In pediatric populations, due to the diameter of the blood vessels, thrombectomy is difficult to perform; additionally, recurrent thrombosis and the need for transfusion of blood products are frequent.

show abstract

Section: Discussionmentioning

confidence: 99%

Fibrinolytic therapy in newborns with superior vena cava syndrome. Case report

et al. 2020

View full text Add to dashboard Cite

show abstract

“…8 Partial response to treatment was defined based on platelet count of >30 x 10 9 /L and doubling of the baseline value and complete response to treatment was defined based on a platelet count of >100x 10 9 /L. 9 Development of bleeding events like gastrointestinal (GIB), skin, mucocutaneous, central nervous system (CNS), genitourinary, epistaxis, hemoptysis, and muscles hematoma were investigated in the setting of COVID-19 infection. Patients with CNS bleeding or who developed hemorrhagic shock secondary to bleeding, or required blood transfusion were considered to have major bleeding events.…”

Section: Methodsmentioning

confidence: 99%

Prognosis of chronic immune thrombocytopenia in the setting of COVID-19 infection

Alayan

Kewan

Alwakeel

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) began to participate effectively in the development of the guidelines of the AMB in 2009, with contributions by several experts as shown in Table 1 ; previously, the collection was limited, with fewer themes. After 2012, guidelines on several diseases were completed and published in the Revista Brasileira de Hematologia e Hemoterapia (RBHH); chronic myelogenous leukemia, 2 multiple myeloma, 3 and diagnosis 4 and treatment of immune thrombocytopenic purpura. 5 It is also important to quote other systematic reviews published in the RBHH, such as preventive practices in longterm hematopoietic stem cell transplantation survivors, with the participation of experts from several different countries.…”

mentioning

confidence: 99%

The Guidelines Project: Brazilian guidelines for acute promyelocytic leukemia

Ruiz¹

2014

Revista Brasileira de Hematologia e Hemoterapia

View full text Add to dashboard Cite

Guidelines on the diagnosis of primary immune thrombocytopenia in children and adolescents: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2012

Cited by 7 publications

References 100 publications

Fibrinolytic therapy in newborns with superior vena cava syndrome. Case report

Fibrinolytic therapy in newborns with superior vena cava syndrome. Case report

Prognosis of chronic immune thrombocytopenia in the setting of COVID-19 infection

The Guidelines Project: Brazilian guidelines for acute promyelocytic leukemia

Contact Info

Product

Resources

About